Mind Medicine Mindmed Inc (MNMD)

$9.59 +0.14 (1.48%)
Market Cap 714.47M
Revenue (ttm) 0.00
Net Income (ttm) -108.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.22
Volume 258,040
Avg Vol 1,218,288
Day's Range N/A - N/A
Shares Out 76.09M
Stochastic %K 25%
Beta 2.49
Analysts Strong Sell
Price Target $25.00

Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is head...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 220 6633
Address:
One World Trade Center, Suite 8500, New York, United States
twiggs462
twiggs462 Aug. 21 at 5:50 PM
$MNMD https://www.linkedin.com/embed/feed/update/urn:li:share:7363281549099745283 Kathryn Tucker, JD 2nd Special Advocacy Advisor, the National Psychedelics Association. Founding Board Member, The Psychedelic Bar Association. End of Life Liberty Advocate. HHS now reviewing the petition to reschedule psilocybin from schedule I to II. DEA has transmitted the February 2022 Petition of our client Dr. Sunil Aggarwal/AIMS Institute to HHS for a medical/scientific evaluation and scheduling recommendation. Multiple clinical trials have demonstrated that psilocybin can bring immediate, substantial, and sustained relief to those suffering debilitating anxiety and depression. This relief is especially important to patients approaching death due to advanced illness and those at risk of suicide due to PTSD. If moved from schedule I to II, this investigational drug would be available under medical supervision before FDA approval under state and federal Right to Try laws. DEA initially denied the Petition. The U.S. Court of Appeals for the Ninth Circuit
0 · Reply
DriuxP
DriuxP Aug. 21 at 4:12 PM
$ATAI $MNMD $CMPS
0 · Reply
twiggs462
twiggs462 Aug. 21 at 3:15 PM
$ATAI $MNMD $CMPS - As soon as one of these hits 1B in valuation the news hype will start again. Then it will really be off on a consistent trend to the finish line for the finale. Keep in mind folks, partnerships, buyouts and regulatory shifts can happen over night. Don't chase. It is really down to these three.
0 · Reply
twiggs462
twiggs462 Aug. 21 at 2:18 PM
$ATAI $MNMD $CMPS - MindMed, Atai, COMPASS are not dumb and are doing exactly what big pharma does (which is good for investors) - Take these examples of "unpatentable" compounds. Don't let the nay sayers tell you the IP doesn't stand. It can and it will. Insulin – Early forms couldn’t be patented (naturally occurring protein). Pharma leveraged patents on recombinant production methods, analog modifications, and delivery devices (pens, pumps). Today, the “evergreening” strategy around insulin pens and analog tweaks is more profitable than the molecule itself. Morphine & other opioids – The core alkaloid is old and unpatentable. Companies created patents on extended-release formulations (e.g., OxyContin), novel salts, or abuse-deterrent technologies. Cannabidiol (CBD) – Not patentable as a natural molecule, but GW Pharmaceuticals secured patents on purification processes, formulations, and medical uses (Epidiolex) which was then bought buy JAZZ.
1 · Reply
Rocketzz
Rocketzz Aug. 21 at 12:21 AM
$MNMD
0 · Reply
dlawler_99
dlawler_99 Aug. 20 at 10:05 PM
$MNMD
0 · Reply
BobbyCucumber
BobbyCucumber Aug. 20 at 8:17 PM
$MNMD
0 · Reply
Dutchindo
Dutchindo Aug. 20 at 11:03 AM
$MNMD
0 · Reply
twiggs462
twiggs462 Aug. 20 at 10:56 AM
$ATAI $MNMD $CMPS - Reimagining Psychedelics: Mental Wellness Without the Roadblocks https://www.pharmaceuticalonline.com/doc/reimagining-psychedelics-mental-wellness-without-the-roadblocks-0001 Tucker is hopeful and excited about the future of psychedelics and their derivatives. Though Lykos’ MDMA therapy was not approved, Tucker believes that prescription psychedelics are in the near future, with encouraging phase 2 and phase 3 results for LSD, 5-methoxy-DMT and psilocybin. And he hopes they get approved, finding that hallucinogenic and non-hallucinogenic treatments can work together to treat mental health disorders in both the short and long term.
0 · Reply
TalkMarkets
TalkMarkets Aug. 19 at 7:47 PM
'Big 5" Psychedelic-Based #Biotech Stocks Up 34% YTD $ATAI $MNMD $CMPS $GHRS $CYBN https://talkmarkets.com/content/stocks--equities/big-5-psychedelic-based-biotech-stocks-up-34-ytd?post=516491
0 · Reply
Latest News on MNMD
MindMed Announces New Employee Inducement Grants

Aug 11, 2025, 4:01 PM EDT - 9 days ago

MindMed Announces New Employee Inducement Grants

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:48 PM EDT - 20 days ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 31, 2025, 4:01 PM EDT - 20 days ago

MindMed Reports Q2 2025 Financial Results and Business Updates

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Jul 24, 2025, 7:00 AM EDT - 4 weeks ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

MindMed to Participate in June Investor Conferences

May 28, 2025, 7:00 AM EDT - 3 months ago

MindMed to Participate in June Investor Conferences

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 27, 2025, 7:00 AM EDT - 3 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 3 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 9:55 AM EDT - 3 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

May 8, 2025, 7:00 AM EDT - 3 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 7:00 AM EDT - 4 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Apr 15, 2025, 7:00 AM EDT - 4 months ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 17, 2025, 7:00 AM EDT - 5 months ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 12:10 PM EST - 6 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 6, 2025, 7:00 AM EST - 6 months ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

MindMed to Present at Leerink's Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 6 months ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 20, 2025, 7:00 AM EST - 6 months ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 7 months ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Jan 30, 2025, 7:00 AM EST - 7 months ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 8 months ago

MindMed to Be Added to the Nasdaq Biotechnology Index

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 16, 2024, 7:00 AM EST - 8 months ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 11, 2024, 7:00 AM EST - 9 months ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 5, 2024, 7:00 AM EST - 9 months ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Dec 3, 2024, 7:00 AM EST - 9 months ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 18, 2024, 7:00 AM EST - 9 months ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

MindMed to Participate in Upcoming Investor Conferences

Nov 13, 2024, 7:00 AM EST - 10 months ago

MindMed to Participate in Upcoming Investor Conferences

Mind Medicine: No News = Good News

Nov 10, 2024, 9:55 AM EST - 10 months ago

Mind Medicine: No News = Good News

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:06 PM EST - 10 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 7, 2024, 4:01 PM EST - 10 months ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Nov 4, 2024, 4:04 PM EST - 10 months ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Oct 24, 2024, 7:00 AM EDT - 10 months ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

MindMed to Participate in September Investor Conferences

Sep 4, 2024, 7:00 AM EDT - 1 year ago

MindMed to Participate in September Investor Conferences

Psychedelic Stocks: Focus On Their Cash

Aug 15, 2024, 12:30 PM EDT - 1 year ago

Psychedelic Stocks: Focus On Their Cash

CMPS

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 11:21 AM EDT - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

MindMed readying Phase III trials for LSD therapy to treat anxiety

Aug 13, 2024, 7:44 AM EDT - 1 year ago

MindMed readying Phase III trials for LSD therapy to treat anxiety

Pacific Defense Announces US Army CMFF Program Team

Aug 13, 2024, 7:01 AM EDT - 1 year ago

Pacific Defense Announces US Army CMFF Program Team

MRNS

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Aug 12, 2024, 12:47 PM EDT - 1 year ago

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CMPS CYBN

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Aug 9, 2024, 8:44 AM EDT - 1 year ago

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Aug 9, 2024, 6:00 AM EDT - 1 year ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy

Aug 7, 2024, 2:29 PM EDT - 1 year ago

MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy

MindMed to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 6, 2024, 4:01 PM EDT - 1 year ago

MindMed to Present at Canaccord Genuity's 44th Annual Growth Conference

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update

Aug 6, 2024, 7:00 AM EDT - 1 year ago

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update

MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Jul 29, 2024, 7:00 AM EDT - 1 year ago

MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Jul 17, 2024, 7:00 AM EDT - 1 year ago

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

MindMed to be Included in Russell 2000® and Russell 3000® Indexes

Jun 28, 2024, 7:00 AM EDT - 1 year ago

MindMed to be Included in Russell 2000® and Russell 3000® Indexes

MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 21, 2024, 7:00 AM EDT - 1 year ago

MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

Jun 20, 2024, 7:00 AM EDT - 1 year ago

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors

Jun 5, 2024, 11:46 AM EDT - 1 year ago

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors

MindMed to Participate in June Conferences

May 28, 2024, 7:00 AM EDT - 1 year ago

MindMed to Participate in June Conferences

twiggs462
twiggs462 Aug. 21 at 5:50 PM
$MNMD https://www.linkedin.com/embed/feed/update/urn:li:share:7363281549099745283 Kathryn Tucker, JD 2nd Special Advocacy Advisor, the National Psychedelics Association. Founding Board Member, The Psychedelic Bar Association. End of Life Liberty Advocate. HHS now reviewing the petition to reschedule psilocybin from schedule I to II. DEA has transmitted the February 2022 Petition of our client Dr. Sunil Aggarwal/AIMS Institute to HHS for a medical/scientific evaluation and scheduling recommendation. Multiple clinical trials have demonstrated that psilocybin can bring immediate, substantial, and sustained relief to those suffering debilitating anxiety and depression. This relief is especially important to patients approaching death due to advanced illness and those at risk of suicide due to PTSD. If moved from schedule I to II, this investigational drug would be available under medical supervision before FDA approval under state and federal Right to Try laws. DEA initially denied the Petition. The U.S. Court of Appeals for the Ninth Circuit
0 · Reply
DriuxP
DriuxP Aug. 21 at 4:12 PM
$ATAI $MNMD $CMPS
0 · Reply
twiggs462
twiggs462 Aug. 21 at 3:15 PM
$ATAI $MNMD $CMPS - As soon as one of these hits 1B in valuation the news hype will start again. Then it will really be off on a consistent trend to the finish line for the finale. Keep in mind folks, partnerships, buyouts and regulatory shifts can happen over night. Don't chase. It is really down to these three.
0 · Reply
twiggs462
twiggs462 Aug. 21 at 2:18 PM
$ATAI $MNMD $CMPS - MindMed, Atai, COMPASS are not dumb and are doing exactly what big pharma does (which is good for investors) - Take these examples of "unpatentable" compounds. Don't let the nay sayers tell you the IP doesn't stand. It can and it will. Insulin – Early forms couldn’t be patented (naturally occurring protein). Pharma leveraged patents on recombinant production methods, analog modifications, and delivery devices (pens, pumps). Today, the “evergreening” strategy around insulin pens and analog tweaks is more profitable than the molecule itself. Morphine & other opioids – The core alkaloid is old and unpatentable. Companies created patents on extended-release formulations (e.g., OxyContin), novel salts, or abuse-deterrent technologies. Cannabidiol (CBD) – Not patentable as a natural molecule, but GW Pharmaceuticals secured patents on purification processes, formulations, and medical uses (Epidiolex) which was then bought buy JAZZ.
1 · Reply
Rocketzz
Rocketzz Aug. 21 at 12:21 AM
$MNMD
0 · Reply
dlawler_99
dlawler_99 Aug. 20 at 10:05 PM
$MNMD
0 · Reply
BobbyCucumber
BobbyCucumber Aug. 20 at 8:17 PM
$MNMD
0 · Reply
Dutchindo
Dutchindo Aug. 20 at 11:03 AM
$MNMD
0 · Reply
twiggs462
twiggs462 Aug. 20 at 10:56 AM
$ATAI $MNMD $CMPS - Reimagining Psychedelics: Mental Wellness Without the Roadblocks https://www.pharmaceuticalonline.com/doc/reimagining-psychedelics-mental-wellness-without-the-roadblocks-0001 Tucker is hopeful and excited about the future of psychedelics and their derivatives. Though Lykos’ MDMA therapy was not approved, Tucker believes that prescription psychedelics are in the near future, with encouraging phase 2 and phase 3 results for LSD, 5-methoxy-DMT and psilocybin. And he hopes they get approved, finding that hallucinogenic and non-hallucinogenic treatments can work together to treat mental health disorders in both the short and long term.
0 · Reply
TalkMarkets
TalkMarkets Aug. 19 at 7:47 PM
'Big 5" Psychedelic-Based #Biotech Stocks Up 34% YTD $ATAI $MNMD $CMPS $GHRS $CYBN https://talkmarkets.com/content/stocks--equities/big-5-psychedelic-based-biotech-stocks-up-34-ytd?post=516491
0 · Reply
DCRMIA
DCRMIA Aug. 19 at 7:31 PM
$MNMD
0 · Reply
twiggs462
twiggs462 Aug. 19 at 5:41 PM
$MNMD Head of Biometrics and Data Science
0 · Reply
twiggs462
twiggs462 Aug. 19 at 5:15 PM
$ATAI $MNMD $CMPS A Trip Through the Psychedelic IP Landscape https://www.lexology.com/library/detail.aspx?g=05ef43c1-9f74-4910-962e-d89801e159a0
0 · Reply
blipper
blipper Aug. 19 at 4:41 PM
$MNMD I like the stonk
0 · Reply
McGuireTO
McGuireTO Aug. 18 at 11:58 PM
$MNMD quickly sets the daily higher low and pokes above $10, but then faded for the last three hours of the day. Red flag? Not yet - Here's what I'm looking for into tomorrow to ensure the short term chart remains healthy, which is crucial given where we are on the long term charts at the moment. I publish regular technical analysis of the psychedelic sector. Be sure to like and follow to not miss an important update! https://www.tradingview.com/chart/MNMD/vcvvCiHF-MNMD-at-a-crucial-point-in-the-longer-term-charts/
0 · Reply
PsychedStocks
PsychedStocks Aug. 18 at 9:32 PM
$CYBN $CMPS $ATAI $MNMD $SPY Cybin Announces Results of Annual Meeting of Shareholders https://ir.cybin.com/investors/news/news-details/2025/Cybin-Announces-Results-of-Annual-Meeting-of-Shareholders/default.aspx
0 · Reply
Eugenian541
Eugenian541 Aug. 18 at 4:58 PM
@traderhr great shares! Would be interested in seeing how you’d chart $MNMD ! Thanks
0 · Reply
CuriousChimps
CuriousChimps Aug. 18 at 4:05 PM
$MNMD
0 · Reply
twiggs462
twiggs462 Aug. 18 at 12:38 PM
$MNMD This applies to MindMed as well.
1 · Reply
twiggs462
twiggs462 Aug. 17 at 9:36 PM
$ATAI $MNMD $CMPS With UCI and other programs, psychedelics soon could be as controversial as aspirin - https://www.ocregister.com/2025/08/17/with-uci-and-other-programs-psychedelics-soon-could-be-as-controversial-as-aspirin/
0 · Reply
twiggs462
twiggs462 Aug. 17 at 9:33 PM
$ATAI $MNMD $CMPS Jillian Michaels Backs RFK Jr.’s Health Movement - https://www.newsbreak.com/the-kansas-city-star-1592484/4177705191347-jillian-michaels-backs-rfk-jr-s-health-movement
1 · Reply
BobbyCucumber
BobbyCucumber Aug. 16 at 3:07 PM
$MNMD DO NOT BELIEVE THE POST BELOW THIS POST, IT WAS POSTED VERBATIM 2 WEEKS AGO, NOW THE ACCOUNT HAS BEEN DELETED!!! MNMD HAS NOT LOST 162 MILLION OF OUR MONEY. THIS IS B******* AND MANIPULATION BY DARK ACTORS...
0 · Reply